Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)

Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)

Submitted by admin on September 9, 2013 - 9:52am
Source: 
Yahoo
News Tags: 
Biodel
BIOD-123
clinical trials
diabetes
type 1 diabetes
Headline: 
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)

Do Not Allow Advertisers to Use My Personal information